Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-13 (**Cancelled**).

14. (**Previously Presented**) A method of preparing a bioabsorbable synthetic nonwoven fabric holding thrombin and fibrinogen as effective ingredients, comprising either

(1) immersing a bioabsorbable synthetic nonwoven fabric made of polyglycolic acid into a saline or buffer solution containing thrombin and lyophilizing, and then immediately prior to use thereof, applying fibrinogen to said nonwoven fabric containing thrombin; or

(2) immediately prior to use, sequentially applying thrombin and fibrinogen onto a bioabsorbable synthetic nonwoven fabric made of polyglycolic acid;

so that said thrombin and said fibrinogen are separated from each other and will not react with one another before use thereof;

wherein the bioabsorable synthetic nonwoven fabric of polyglycolic acid is a needle-punched and elastic polyglycolic acid fabric.

Claims 15 and 16 (**Cancelled**).

17. (**Previously Presented**) The method according to claim 14, wherein said hemostatic material comprises at least one additive selected from Factor XIII, a protease inhibitor, or calcium chloride.

18. (**Previously presented**) The method according to claim 17, wherein said calcium chloride is fixed to the bioabsorbable synthetic nonwoven fabric together with thrombin.

19. (**Previously presented**) The method according to claim 17, wherein said Factor XIII is added to fibrinogen.

20. (**Previously presented**) The method according to claim 14, wherein said thrombin, fibrinogen and Factor XIII are either derived from human blood or produced by a genetic recombination technique.

21. (**Previously presented**) A hemostatic kit consisting of

a bioabsorbable synthetic nonwoven needle-punched and elastic fabric made of polyglycolic acid holding thrombin as an effective ingredient,

a container comprising fibrinogen as an effective ingredient, and

optionally at least one additive.

Claims 22-23 (**Cancelled**).

24. (**Previously Presented**) The hemostatic kit according to claim 21, wherein said hemostatic kit comprises said at least one additive selected from Factor XIII, a protease inhibitor, or calcium chloride.

25. (**Original**) The hemostatic kit according to claim 24, wherein said calcium chloride is added to the bioabsorbable synthetic nonwoven fabric as an additive for thrombin.

26. (**Previously presented**) The hemostatic kit according to claim 24, wherein said Factor XIII is included in a container comprising fibrinogen.

27. (**Previously presented**) The hemostatic kit according to claim 21, wherein said thrombin, fibrinogen and Factor XIII are either derived from human blood or produced by a genetic recombination technique.

28. (**Previously presented**) The hemostatic kit according to claim 21, wherein said bioabsorbable synthetic nonwoven fabric holding thrombin is prepared by the steps of immersing a bioabsorbable synthetic nonwoven fabric into a solution containing thrombin and of lyophilizing the obtained nonwoven fabric.

29. (**Previously presented**) A hemostatic kit consisting of

a bioabsorbable synthetic nonwoven needle-punched and elastic fabric made of polyglycolic acid as a substrate,

a container comprising thrombin as an effective ingredient,

a container comprising fibrinogen as an effective ingredient, and

optionally at least one additive.

Claims 30-31 (**Cancelled**).

32. (**Previously Presented**) The hemostatic kit according to claim 29, wherein said hemostatic kit comprises said at least one additive selected from Factor XIII, a protease inhibitor, or calcium chloride.

33. (**Original**) The hemostatic kit according to claim 32, wherein said Factor XIII is included in a container comprising fibrinogen.

34. (**Previously Presented**) The hemostatic kit according to claim 29, wherein said thrombin, fibrinogen and Factor XIII are either derived from human blood or produced by a genetic recombination technique.

Claim 35 (**Cancelled**).

36. (**Currently Amended**) In a hemostatic material comprising

thrombin and fibrinogen as an effective combination of ingredients, and a substrate for holding said thrombin and fibrinogen, the improvement wherein

said substrate is a bioabsorbable synthetic nonwoven fabric made of polyglycolic acid, and

said hemostatic material optionally comprises an additive;

wherein said hemostatic material is only selected from the group consisting of

(1) (i) thrombin held on said bioabsorbable synthetic nonwoven fabric, and (ii) fibrinogen added immediately prior to

use, and

(2) (i) said bioabsorbable synthetic nonwoven fabric, (ii) thrombin added immediately prior to use, and (iii) fibrinogen added immediately prior to use,

wherein said bioabsorbable synthetic nonwoven fabric is a needle-punched ~~and elastic~~ fabric made of polyglycolic acid, and having sufficient flexibility and elasticity to ensure sticking to an affected area of approximately any shape.

37. (**Previously Presented**) The hemostatic material according to claim 36, wherein said hemostatic material comprises said at least one additive selected from Factor XIII, a protease inhibitor, or calcium chloride.

38. (**Previously Presented**) The hemostatic material according to claim 37, wherein thrombin, fibrinogen and Factor XIII are either derived from human blood or produced by a genetic recombination technique.

Claims 39-40 (**Cancelled**).

41. (**New**) The method of claim 14, further comprising applying the bioabsorbable synthetic nonwoven fabric holding thrombin and fibrinogen against a wound suffering projectile bleeding.